Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

Status:
RECRUITING

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

PHASE2

Evommune, Inc.